Basis of Presentation, Liquidity and Risks and Uncertainties	6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]
Basis of Presentation, Liquidity and Risks and Uncertainties	Basis of Presentation, Liquidity and Risks and Uncertainties Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) as contained in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of June 30, 2026, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and six months ended June 30, 2026 and 2025 and the condensed consolidated statements of cash flows for the six months ended June 30, 2026 and 2025 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three and six months ended June 30, 2026 shown herein are not necessarily indicative of the results that may be expected for the year ending December 31, 2026, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2025, included in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 12, 2026. The balance sheet at December 31, 2025 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of June 30, 2026 and December 31, 2025, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. Liquidity The Company incurred a net loss of $6.0 million and $25.7 million for the three and six months ended June 30, 2026, respectively. The Company had working capital of $(2,000) and an accumulated deficit of $1.8 billion as of June 30, 2026. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. On July 31, 2026, the Company closed an underwritten public offering (the “July 2026 Offering”) relating to the issuance and sale by the Company of 21,052,632 shares of its common stock, par value $0.001 per share, and accompanying warrants (the "July 2026 Warrants") to purchase up to 42,105,264 shares of its common stock (or pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”)), at an exercise price of $1.10 per share of common stock (or $1.099 per Pre-Funded Warrant to purchase a share of common stock), at a combined public offering price of $0.95 per share of common stock and accompanying July 2026 Warrant. The Company also granted the Underwriter an option for a period of 30 days to purchase up to 3,157,894 additional shares of common stock and/or July 2026 Warrants to purchase up to 6,315,788 additional shares of common stock (or pre-funded warrants in lieu thereof) at the public offering price, less the underwriting discounts and commissions. On July 29, 2026, the Underwriter exercised such option with respect to the July 2026 Warrants to purchase up to 6,315,788 additional shares of common stock (or pre-funded warrants in lieu thereof). The net proceeds to the Company from the July 2026 Offering, including the exercise of the Underwriter's option to purchase additional warrants, were approximately $18.3 million, after deducting the underwriting discounts and commissions and offering expenses paid and payable by the Company, and assuming no exercise of the Underwriter's option to purchase additional shares. On April 6, 2026, the Company closed an underwritten public offering (the “April 2026 Offering”) relating to the issuance and sale by the Company of 12,500,000 shares of its common stock, par value $0.001 per share, and accompanying Series A warrants to purchase up to 12,500,000 shares of its common stock (or pre-funded warrants, each representing the right to purchase one share of common stock at an exercise price of $0.001 (the “Pre-Funded Warrants”) in lieu thereof) at an exercise price of $1.40 per share of common stock (or $1.399 per Pre-Funded Warrant) (the “April 2026 Series A Warrants”) and Series B warrants to purchase up to 12,500,000 shares of its common stock (or Pre-Funded Warrants in lieu thereof) at an exercise price of $1.40 per share of common stock (or $1.399 per Pre-Funded Warrant) (the “April 2026 Series B Warrants” and, together with the 2026 Series A Warrants, the “2026 Warrants”), at a combined public offering price of $1.40 per share of common stock and accompanying 2026 Warrants. The net proceeds to the Company from the April 2026 Offering were $16.1 million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. On November 12, 2025, the Company closed an underwritten public offering (the “November 2025 Offering”) relating to the issuance and sale of 15,131,700 shares of its common stock, par value $0.001 per share, at an offering price of $1.90 per share. The net proceeds to the Company from the November 2025 Offering were $26.6 million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. On July 7, 2025, the Company closed an underwritten public offering (the “July 2025 Offering”) relating to the issuance and sale by the Company of 14,285,715 shares of its common stock, par value $0.001 per share, and accompanying Series A warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants, each representing the right to purchase one share of common stock at an exercise price of $0.001 (the “Pre-Funded Warrants”) in lieu thereof) at an exercise price of $1.75 per share of common stock (or $1.749 per Pre-Funded Warrant) (the “2025 Series A Warrants”) and Series B warrants to purchase up to 14,285,715 shares of its common stock (or Pre-Funded Warrants in lieu thereof) at an exercise price of $1.75 per share of common stock (or $1.749 per Pre-Funded Warrant) (the “2025 Series B Warrants” and, together with the 2025 Series A Warrants, the “2025 Warrants”), at a combined public offering price of $1.75 per share of common stock and accompanying 2025 Warrants. The net proceeds to the Company from the July 2025 Offering were $22.4 million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. Going Concern The Company’s cash, cash equivalents and short-term investments of $36.7 million as of June 30, 2026, together with the net proceeds from the July 2026 Offering, are expected to be sufficient to support the Company's planned operations through a potential launch of INO-3107, if approved, and into late first quarter 2027. The Company's current financial resources may not be sufficient to support its planned operations beyond this date without securing additional financing. In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (“Sales Agreements”). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of approximately $18.3 million from the July 2026 Offering, $16.1 million from the April 2026 Offering, $49.0 million from equity offerings during the year ended December 31, 2025, and the receipt of net proceeds of $1.1 million under Sales Agreements for both the six months ended June 30, 2026 and year ended December 31, 2025. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs. The Company’s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and may never achieve positive cash flow. In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the first quarter of 2027. The Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2026 do not include any adjustments that might result from the outcome of this uncertainty. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements. The Company is, and from time to time may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails. Any of the foregoing consequences could result in serious harm to the Company’s business, results of operations and financial condition.

The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) as contained in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of June 30, 2026, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and six months ended June 30, 2026 and 2025 and the condensed consolidated statements of cash flows for the six months ended June 30, 2026 and 2025 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented.

The results of operations for the three and six months ended June 30, 2026 shown herein are not necessarily indicative of the results that may be expected for the year ending December 31, 2026, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2025, included in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 12, 2026. The balance sheet at December 31, 2025 has been derived from the audited

These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of June 30, 2026 and December 31, 2025, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation.

The Company incurred a net loss of $6.0 million and $25.7 million for the three and six months ended June 30, 2026, respectively. The Company had working capital of $(2,000) and an accumulated deficit of $1.8 billion as of June 30, 2026. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates.

On July 31, 2026, the Company closed an underwritten public offering (the “July 2026 Offering”) relating to the issuance and sale by the Company of 21,052,632 shares of its common stock, par value $0.001 per share, and accompanying warrants (the "July 2026 Warrants") to purchase up to 42,105,264 shares of its common stock (or pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”)), at an exercise price of $1.10 per share of common stock (or $1.099 per Pre-Funded Warrant to purchase a share of common stock), at a combined public offering price of $0.95 per share of common stock and accompanying July 2026 Warrant.

The Company also granted the Underwriter an option for a period of 30 days to purchase up to 3,157,894 additional shares of common stock and/or July 2026 Warrants to purchase up to 6,315,788 additional shares of common stock (or pre-funded warrants in lieu thereof) at the public offering price, less the underwriting discounts and commissions. On July 29, 2026, the Underwriter exercised such option with respect to the July 2026 Warrants to purchase up to 6,315,788 additional shares of common stock (or pre-funded warrants in lieu thereof).

The net proceeds to the Company from the July 2026 Offering, including the exercise of the Underwriter's option to purchase additional warrants, were approximately $18.3 million, after deducting the underwriting discounts and commissions and offering expenses paid and payable by the Company, and assuming no exercise of the Underwriter's option to purchase additional shares.

On April 6, 2026, the Company closed an underwritten public offering (the “April 2026 Offering”) relating to the issuance and sale by the Company of 12,500,000 shares of its common stock, par value $0.001 per share, and accompanying Series A warrants to purchase up to 12,500,000 shares of its common stock (or pre-funded warrants, each representing the right to purchase one share of common stock at an exercise price of $0.001 (the “Pre-Funded Warrants”) in lieu thereof) at an exercise price of $1.40 per share of common stock (or $1.399 per Pre-Funded Warrant) (the “April 2026 Series A Warrants”) and Series B warrants to purchase up to 12,500,000 shares of its common stock (or Pre-Funded Warrants in lieu thereof) at an exercise price of $1.40 per share of common stock (or $1.399 per Pre-Funded Warrant) (the “April 2026 Series B Warrants” and, together with the 2026 Series A Warrants, the “2026 Warrants”), at a combined public offering price of $1.40 per share of common stock and accompanying 2026 Warrants. The net proceeds to the Company from the April 2026 Offering were $16.1 million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company.

On November 12, 2025, the Company closed an underwritten public offering (the “November 2025 Offering”) relating to the issuance and sale of 15,131,700 shares of its common stock, par value $0.001 per share, at an offering price of $1.90 per share. The net proceeds to the Company from the November 2025 Offering were $26.6 million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company.

On July 7, 2025, the Company closed an underwritten public offering (the “July 2025 Offering”) relating to the issuance and sale by the Company of 14,285,715 shares of its common stock, par value $0.001 per share, and accompanying Series A warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants, each representing the right to purchase one share of common stock at an exercise price of $0.001 (the “Pre-Funded Warrants”) in lieu thereof) at an exercise price of $1.75 per share of common stock (or $1.749 per Pre-Funded Warrant) (the “2025 Series A Warrants”) and Series B warrants to purchase up to 14,285,715 shares of its common stock (or Pre-Funded Warrants in lieu thereof) at an exercise price of $1.75 per share of common stock (or $1.749 per Pre-Funded Warrant) (the “2025 Series B Warrants” and, together with the 2025 Series A Warrants, the “2025 Warrants”), at a combined public offering price of $1.75 per share of common stock and accompanying 2025 Warrants. The net proceeds to the Company from the July 2025 Offering were $22.4 million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company.

The Company’s cash, cash equivalents and short-term investments of $36.7 million as of June 30, 2026, together with the net proceeds from the July 2026 Offering, are expected to be sufficient to support the Company's planned operations through a

In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (“Sales Agreements”). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of approximately $18.3 million from the July 2026 Offering, $16.1 million from the April 2026 Offering, $49.0 million from equity offerings during the year ended December 31, 2025, and the receipt of net proceeds of $1.1 million under Sales Agreements for both the six months ended June 30, 2026 and year ended December 31, 2025. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.

The Company’s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and may never achieve positive cash flow. In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the first quarter of 2027. The Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2026 do not include any adjustments that might result from the outcome of this uncertainty. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.